Paraquat

Paraquat

SCHEMBL4086035

C[n+]1ccc(-c2cc[n+](C)cc2)cc1.Cc1ccc(S(=O)(=O)[O-])cc1.Cc1ccc(S(=O)(=O)[O-])cc1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Paraquat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 1/20 0.59
GAA P10253 3/20 0.45
SLC6A4 P31645 2/20 0.43
SLC22A2 O15244 1/20 0.43
SLC22A1 O15245 1/20 0.43
SLC22A3 O75751 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
TLR9 Q9NR96 1/20 0.41
ALDH1A1 P00352 2/20 0.40
PKM P14618 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
PABPC1 P11940 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001154 0.92 TERT (0.55) TERTGAACA12CA1CA2
SCHEMBL10844389 0.90 PABPC1 (0.58) TERTGAASLC6A4SLC22A2SLC22A1
SCHEMBL1982598 0.85 TERT (0.49) TERTGAACA12CA1CA2
Alcohol SCHEMBL27993658 0.84 TERT (0.49) TERTGAACA12CA1CA2
SCHEMBL3774913 0.84 TERT (0.49) TERTGAACA12CA1CA2
SCHEMBL31397607 0.83 TERT (0.48) TERTGAASLC6A4SLC22A2SLC22A1
SCHEMBL7047125 0.82 CYP2A6 (0.48) TERTGAACA12CA1CA2
SCHEMBL8987883 0.81 TERT (0.50) TERTGAACA12CA1CA2
SCHEMBL9864698 0.81 GAA (0.54) GAACA12CA1CA2CA3
SCHEMBL24352 0.81 MAPT (0.49) TERTGAACA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7500895-B2 Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device SEIKO EPSON CORPORATION (JP) 2009-03-10 US disclosed
US-20060127563-A1 Patterned substrate, electro-optical device, and method for manufacturing an electro-optical device SEIKO EPSON CORPORATION (JP) 2006-06-15 US disclosed
US-20050287392-A1 Organic electroluminescent device, method for producing the same, and electronic apparatus SEIKO EPSON CORPORATION (JP) 2005-12-29 US disclosed
US-20050209459-A1 Processes for the preparation of 1,5-diryl-3-substituted-pyrazoles REDDY M V R 2005-09-22 US disclosed
US-6906196-B2 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles ONCONOVA THERAPEUTICS, INC. (US) 2005-06-14 US disclosed
US-6706927-B2 INTERMEDIATES IN PREPARATION OF 1,5-DIARYLPYRAZOLE ANTIINFLAMMATORY AGENTS ONCONOVA THERAPEUTICS, INC. 2004-03-16 US disclosed
US-20030199707-A1 ALKYNE KETONES ONCONOVA THERAPEUTICS, INC. 2003-10-23 US disclosed
US-6579988-B2 Condensation cyclization of an alkyne and a para-sulfone or sulfonamide phenyl hydrazine ONCONOVA THERAPEUTICS, INC. 2003-06-17 US disclosed
US-20030109709-A1 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles ONCONOVA THERAPEUTICS, INC. 2003-06-12 US disclosed
US-20030096853-A1 PROCESSES FOR THE PREPARATION OF 1,5-DIARYLPYRAZOLES ONCONOVA THERAPEUTICS, INC. 2003-05-22 US disclosed
WO-2003024400-A2 PROCESS FOR THE PREPARATION OF 1,5-DIARYLPYRAZOLES ONCONOVA THERAPEUTICS, INC. (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209459-A1 Processes for the preparation of 1,5-diryl-3-substituted-pyrazoles CYP2E1, CYP1A1, CYP1B1 TERT 486/4885GAA 3728/4885SLC6A4 3985/4885
US-20030096853-A1 PROCESSES FOR THE PREPARATION OF 1,5-DIARYLPYRAZOLES CBR1, CYP1A1, CYP1B1 TERT 898/4885GAA 4757/4885SLC6A4 3252/4885
US-20030199707-A1 ALKYNE KETONES CBR1, CBR3, CYC1 TERT 1302/4885GAA 4696/4885SLC6A4 3774/4885
US-20030109709-A1 Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles CYP1B1, CYP1A1, CYP2E1 TERT 460/4885GAA 3780/4885SLC6A4 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.